Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jun;103(6):e277-e278.
doi: 10.3324/haematol.2018.191122. Epub 2018 Apr 5.

Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma

Serena Rocchi  1 , Paola Tacchetti  1 , Lucia Pantani  1 , Katia Mancuso  1 , Beatrice Zannetti  1 , Michele Cavo  2 , Elena Zamagni  1
Affiliations
Case Reports

Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma

Serena Rocchi et al. Haematologica. 2018 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trend of dFLC from first to fifth line of treatment. The main vertical axis shows the dFLC values (mg/L) at diagnosis and during treatment. The horizontal axis shows the sequential lines of treatment over time (months). dFLC: difference between involved and uninvolved serum-free light chains.
See this image and copyright information in PMC

References

    1. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394. - PMC - PubMed
    1. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015; 373(13):1207–1219. - PubMed
    1. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560. - PubMed
    1. Usmani SZ, Weiss BM, Plesner T, et al. Clinical Efficacy of Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37–44. - PMC - PubMed
    1. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331. - PubMed

MeSH terms